Search research articles
Contact Us
Filters
Showing results (21-30 of 383) with videos related to
Page
of 39
Sort By:
Current Opinion in Oncology
|
March 23, 2021
Sinonasal cancers treatments: state of the art
Marco Ferrari, Ester Orlandi, Paolo Bossi
The New England Journal of Medicine
|
March 15, 2008
TP53 mutations in head and neck cancer
Federica Perrone, Paolo Bossi, Lisa Licitra
Expert Opinion on Emerging Drugs
|
October 8, 2013
Emerging tyrosine kinase inhibitors for head and neck cancer
Paolo Bossi, Laura Locati, Lisa Licitra
Dermatology Practical & Conceptual
|
November 22, 2023
Advanced Cutaneous Squamous Cell Carcinoma Management in Immunotherapy Era: Achievements and New Challenges
Luigi Lorini, Andrea Alberti, Paolo Bossi
British Journal of Cancer
|
August 12, 2015
Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base'
Paolo Bossi, Ester Orlandi, Lisa Licitra
JAMA
|
November 28, 2023
Immunotherapy for Nasopharyngeal Carcinoma: The Earlier the Better
Paolo Bossi, Cristina Gurizzan, Anthony Chan
Current Opinion in Otolaryngology & Head and Neck Surgery
|
January 4, 2021
Oral potentially malignant disorders: new insights for future treatment
Crisitna Gurizzan, Luigi Lorini, Paolo Bossi
Current Treatment Options in Oncology
|
October 29, 2017
The Case Volume Issue in Head and Neck Oncology
Salvatore Alfieri, Ester Orlandi, Paolo Bossi
Current Opinion in Otolaryngology & Head and Neck Surgery
|
January 30, 2019
Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice
Petr Szturz, Paolo Bossi, Jan B Vermorken
Expert Review of Anticancer Therapy
|
November 21, 2007
Biological agents in head and neck cancer
Paolo Bossi, Laura D Locati, Lisa Licitra
Page
of 39
Search research articles
Search
Showing results (21-30 of 383) with videos related to
Sort By:
Page
of 39
Current Opinion in Oncology
|
March 23, 2021
Sinonasal cancers treatments: state of the art
Marco Ferrari, Ester Orlandi, Paolo Bossi
The New England Journal of Medicine
|
March 15, 2008
TP53 mutations in head and neck cancer
Federica Perrone, Paolo Bossi, Lisa Licitra
Expert Opinion on Emerging Drugs
|
October 8, 2013
Emerging tyrosine kinase inhibitors for head and neck cancer
Paolo Bossi, Laura Locati, Lisa Licitra
Dermatology Practical & Conceptual
|
November 22, 2023
Advanced Cutaneous Squamous Cell Carcinoma Management in Immunotherapy Era: Achievements and New Challenges
Luigi Lorini, Andrea Alberti, Paolo Bossi
British Journal of Cancer
|
August 12, 2015
Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base'
Paolo Bossi, Ester Orlandi, Lisa Licitra
JAMA
|
November 28, 2023
Immunotherapy for Nasopharyngeal Carcinoma: The Earlier the Better
Paolo Bossi, Cristina Gurizzan, Anthony Chan
Current Opinion in Otolaryngology & Head and Neck Surgery
|
January 4, 2021
Oral potentially malignant disorders: new insights for future treatment
Crisitna Gurizzan, Luigi Lorini, Paolo Bossi
Current Treatment Options in Oncology
|
October 29, 2017
The Case Volume Issue in Head and Neck Oncology
Salvatore Alfieri, Ester Orlandi, Paolo Bossi
Current Opinion in Otolaryngology & Head and Neck Surgery
|
January 30, 2019
Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice
Petr Szturz, Paolo Bossi, Jan B Vermorken
Expert Review of Anticancer Therapy
|
November 21, 2007
Biological agents in head and neck cancer
Paolo Bossi, Laura D Locati, Lisa Licitra
Page
of 39